How much revenue did Merck KGaA generate this year?
Merck KGaA has achieved a revenue of 21.52 B EUR this year.
Merck KGaA Revenue 2024
Merck KGaA Revenue
21.52 B EUR
Ticker
MRK.DE
ISIN
DE0006599905
WKN
659990
In 2024, Merck KGaA's sales reached 21.52 B EUR, a 2.53% difference from the 20.99 B EUR sales recorded in the previous year.
The Merck KGaA Revenue history
| YEAR | REVENUE (undefined EUR) | GROSS MARGIN (%) |
|---|---|---|
| 2029e | 25.9 | 48,74 |
| 2028e | 25.81 | 48,90 |
| 2027e | 24.99 | 50,51 |
| 2026e | 23.87 | 52,88 |
| 2025e | 22.77 | 55,44 |
| 2024e | 21.52 | 58,65 |
| 2023 | 20.99 | 60,13 |
| 2022 | 22.23 | 62,16 |
| 2021 | 19.69 | 62,79 |
| 2020 | 17.53 | 61,32 |
| 2019 | 16.15 | 63,16 |
| 2018 | 14.84 | 63,99 |
| 2017 | 14.52 | 65,07 |
| 2016 | 15.02 | 65,38 |
| 2015 | 12.84 | 68,26 |
| 2014 | 11.36 | 68,97 |
| 2013 | 11.1 | 73,03 |
| 2012 | 11.17 | 71,74 |
| 2011 | 10.28 | 72,87 |
| 2010 | 9.29 | 74,32 |
| 2009 | 7.75 | 73,81 |
| 2008 | 7.56 | 74,78 |
| 2007 | 7.06 | 74,78 |
| 2006 | 6.28 | 61,58 |
| 2005 | 5.97 | 60,30 |
| 2004 | 5.47 | 58,91 |
Merck KGaA Revenue, EBIT, Net Income DE0006599905 · 659990
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Merck KGaA, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Merck KGaA from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Merck KGaA’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Merck KGaA. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Merck KGaA’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Merck KGaA’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Merck KGaA’s growth potential.
Merck KGaA Revenue, Profit, and EBIT History
| Date | Merck KGaA Revenue | Merck KGaA EBIT | Merck KGaA Net Income |
|---|---|---|---|
| 2029e | 25.9 B undefined | 0 undefined | 1.66 B undefined |
| 2028e | 25.81 B undefined | 5.84 B undefined | 1.54 B undefined |
| 2027e | 24.99 B undefined | 5.44 B undefined | 1.47 B undefined |
| 2026e | 23.87 B undefined | 5.39 B undefined | 1.4 B undefined |
| 2025e | 22.77 B undefined | 5 B undefined | 1.29 B undefined |
| 2024e | 21.52 B undefined | 3.91 B undefined | 1.13 B undefined |
| 2023 | 20.99 B undefined | 4.22 B undefined | 2.82 B undefined |
| 2022 | 22.23 B undefined | 5.26 B undefined | 3.33 B undefined |
| 2021 | 19.69 B undefined | 4.36 B undefined | 3.06 B undefined |
| 2020 | 17.53 B undefined | 3.07 B undefined | 1.99 B undefined |
| 2019 | 16.15 B undefined | 2.51 B undefined | 1.32 B undefined |
| 2018 | 14.84 B undefined | 2.13 B undefined | 3.37 B undefined |
| 2017 | 14.52 B undefined | 2.4 B undefined | 2.61 B undefined |
| 2016 | 15.02 B undefined | 2.49 B undefined | 1.63 B undefined |
| 2015 | 12.84 B undefined | 2.24 B undefined | 1.11 B undefined |
| 2014 | 11.36 B undefined | 1.84 B undefined | 1.16 B undefined |
| 2013 | 11.1 B undefined | 2.14 B undefined | 1.2 B undefined |
| 2012 | 11.17 B undefined | 1.89 B undefined | 567 M undefined |
| 2011 | 10.28 B undefined | 1.42 B undefined | 618 M undefined |
| 2010 | 9.29 B undefined | 1.4 B undefined | 632 M undefined |
| 2009 | 7.75 B undefined | 870 M undefined | 366 M undefined |
| 2008 | 7.56 B undefined | 1.19 B undefined | 367 M undefined |
| 2007 | 7.06 B undefined | 1.24 B undefined | 3.5 B undefined |
| 2006 | 6.28 B undefined | 1.11 B undefined | 983 M undefined |
| 2005 | 5.97 B undefined | 882 M undefined | 659 M undefined |
| 2004 | 5.47 B undefined | 748 M undefined | 659 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 5.47 B EUR | 748 M EUR | 659 M EUR |
| 2005 | 5.97 B EUR | 882 M EUR | 659 M EUR |
| 2006 | 6.28 B EUR | 1.11 B EUR | 983 M EUR |
| 2007 | 7.06 B EUR | 1.24 B EUR | 3.5 B EUR |
| 2008 | 7.56 B EUR | 1.19 B EUR | 367 M EUR |
| 2009 | 7.75 B EUR | 870 M EUR | 366 M EUR |
| 2010 | 9.29 B EUR | 1.4 B EUR | 632 M EUR |
| 2011 | 10.28 B EUR | 1.42 B EUR | 618 M EUR |
| 2012 | 11.17 B EUR | 1.89 B EUR | 567 M EUR |
| 2013 | 11.1 B EUR | 2.14 B EUR | 1.2 B EUR |
| 2014 | 11.36 B EUR | 1.84 B EUR | 1.16 B EUR |
| 2015 | 12.84 B EUR | 2.24 B EUR | 1.11 B EUR |
| 2016 | 15.02 B EUR | 2.49 B EUR | 1.63 B EUR |
| 2017 | 14.52 B EUR | 2.4 B EUR | 2.61 B EUR |
| 2018 | 14.84 B EUR | 2.13 B EUR | 3.37 B EUR |
| 2019 | 16.15 B EUR | 2.51 B EUR | 1.32 B EUR |
| 2020 | 17.53 B EUR | 3.07 B EUR | 1.99 B EUR |
| 2021 | 19.69 B EUR | 4.36 B EUR | 3.06 B EUR |
| 2022 | 22.23 B EUR | 5.26 B EUR | 3.33 B EUR |
| 2023 | 20.99 B EUR | 4.22 B EUR | 2.82 B EUR |
| 2024e | 21.52 B EUR | 3.91 B EUR | 1.13 B EUR |
| 2025e | 22.77 B EUR | 5 B EUR | 1.29 B EUR |
| 2026e | 23.87 B EUR | 5.39 B EUR | 1.4 B EUR |
| 2027e | 24.99 B EUR | 5.44 B EUR | 1.47 B EUR |
| 2028e | 25.81 B EUR | 5.84 B EUR | 1.54 B EUR |
| 2029e | 25.9 B EUR | 0 EUR | 1.66 B EUR |
Merck KGaA stock margins DE0006599905 · 659990
The Merck KGaA margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Merck KGaA. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Merck KGaA.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Merck KGaA's sales revenue. A higher gross margin percentage indicates that the Merck KGaA retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Merck KGaA's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Merck KGaA's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Merck KGaA's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Merck KGaA. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Merck KGaA's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Merck KGaA Margin History
| Merck KGaA Gross margin | Merck KGaA Profit margin | Merck KGaA EBIT margin | Merck KGaA Profit margin |
|---|---|---|---|
| 2029e | 60.13 % | 0 % | 6.42 % |
| 2028e | 60.13 % | 22.63 % | 5.96 % |
| 2027e | 60.13 % | 21.77 % | 5.87 % |
| 2026e | 60.13 % | 22.56 % | 5.86 % |
| 2025e | 60.13 % | 21.97 % | 5.66 % |
| 2024e | 60.13 % | 18.15 % | 5.23 % |
| 2023 | 60.13 % | 20.11 % | 13.45 % |
| 2022 | 62.16 % | 23.64 % | 14.96 % |
| 2021 | 62.79 % | 22.17 % | 15.52 % |
| 2020 | 61.32 % | 17.51 % | 11.33 % |
| 2019 | 63.16 % | 15.53 % | 8.17 % |
| 2018 | 63.99 % | 14.34 % | 22.74 % |
| 2017 | 65.07 % | 16.53 % | 17.94 % |
| 2016 | 65.38 % | 16.59 % | 10.84 % |
| 2015 | 68.26 % | 17.47 % | 8.68 % |
| 2014 | 68.97 % | 16.16 % | 10.18 % |
| 2013 | 73.03 % | 19.25 % | 10.83 % |
| 2012 | 71.74 % | 16.92 % | 5.07 % |
| 2011 | 72.87 % | 13.82 % | 6.01 % |
| 2010 | 74.32 % | 15.1 % | 6.8 % |
| 2009 | 73.81 % | 11.23 % | 4.72 % |
| 2008 | 74.78 % | 15.71 % | 4.86 % |
| 2007 | 74.78 % | 17.59 % | 49.6 % |
| 2006 | 61.58 % | 17.6 % | 15.64 % |
| 2005 | 60.3 % | 14.78 % | 11.04 % |
| 2004 | 58.91 % | 13.66 % | 12.04 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 58.91 % | 13.66 % | 12.04 % |
| 2005 | 60.3 % | 14.78 % | 11.04 % |
| 2006 | 61.58 % | 17.6 % | 15.64 % |
| 2007 | 74.78 % | 17.59 % | 49.6 % |
| 2008 | 74.78 % | 15.71 % | 4.86 % |
| 2009 | 73.81 % | 11.23 % | 4.72 % |
| 2010 | 74.32 % | 15.1 % | 6.8 % |
| 2011 | 72.87 % | 13.82 % | 6.01 % |
| 2012 | 71.74 % | 16.92 % | 5.07 % |
| 2013 | 73.03 % | 19.25 % | 10.83 % |
| 2014 | 68.97 % | 16.16 % | 10.18 % |
| 2015 | 68.26 % | 17.47 % | 8.68 % |
| 2016 | 65.38 % | 16.59 % | 10.84 % |
| 2017 | 65.07 % | 16.53 % | 17.94 % |
| 2018 | 63.99 % | 14.34 % | 22.74 % |
| 2019 | 63.16 % | 15.53 % | 8.17 % |
| 2020 | 61.32 % | 17.51 % | 11.33 % |
| 2021 | 62.79 % | 22.17 % | 15.52 % |
| 2022 | 62.16 % | 23.64 % | 14.96 % |
| 2023 | 60.13 % | 20.11 % | 13.45 % |
| 2024e | 60.13 % | 18.15 % | 5.23 % |
| 2025e | 60.13 % | 21.97 % | 5.66 % |
| 2026e | 60.13 % | 22.56 % | 5.86 % |
| 2027e | 60.13 % | 21.77 % | 5.87 % |
| 2028e | 60.13 % | 22.63 % | 5.96 % |
| 2029e | 60.13 % | 0 % | 6.42 % |
Merck KGaA Aktienanalyse
What does Merck KGaA do?
Merck is one of the oldest and most well-known companies in the pharmaceutical and chemical industry. It was founded as a pharmacy in Darmstadt in 1668 and has since developed into a global company that is successful worldwide. Merck's business model is based on various business areas, all of which are based on scientific research and innovation. The three main business areas are the Life Science, Healthcare, and Performance Materials divisions, all of which focus on providing products and services for a wide range of industries. Life Science is Merck's largest business area, focusing on providing materials, products, instruments, and services for scientific research and biopharmaceutical production. The company offers a wide range of products that focus on the work of researchers and scientists in molecular biology, cell technology, and genomics. Healthcare is another important business area for Merck, focusing on the manufacture and marketing of innovative drugs and treatments for patients. The company offers products for the treatment of diseases such as cancer, multiple sclerosis, and schizophrenia. Performance Materials is Merck's third business area, specializing in the production of materials and technologies for various industries such as the automotive industry, electronics, and packaging. The company focuses on the development of innovative materials such as liquid crystals and organic photovoltaic materials. Merck is also known for its research and development, and the company invests significant resources in developing new products and technologies. This is also evident in the extensive portfolio of products offered by Merck. The company offers a wide range of products ranging from laboratory and analysis equipment to pharmaceuticals and biopharmaceuticals to specialty chemicals. An example of an important product from Merck is the rheumatoid arthritis drug Remicade, which was developed in collaboration with Johnson & Johnson. Merck is also one of the leading manufacturers of liquid crystals for use in displays and electronic devices. Merck is a company committed to social responsibility and sustainability. The company is involved in many areas, including environmental, social, and governance issues. Merck is committed to developing sustainable products and technologies and is dedicated to promoting education, health, and social justice in the communities where it operates. Overall, Merck is a leading company in the pharmaceutical and chemical industry, known for its innovation, research and development, as well as its social responsibility and sustainability. With currently approximately 58,000 employees and annual sales of 17.4 billion euros, the global company network is represented in 67 countries and demonstrates the quality and capabilities of the company worldwide. Merck KGaA ist eines der beliebtesten Unternehmen auf Eulerpool.com.Merck KGaA revenue by segment
In the annual report of the Merck KGaA share (DE0006599905, 659990, MRK.DE), it breaks down its revenues into 3 segments: 1. Life Science, 2. Healthcare, 3. Performance Materials. The Merck KGaA stock (WKN: 659990, ISIN: DE0006599905, Ticker Symbol: MRK.DE) is a leading investment for investors interested in participating in the Health Care sector.
42 % Life Science
42 % Healthcare
16 % Performance Materials
Revenue Details
Understanding Merck KGaA's Sales Figures
The sales figures of Merck KGaA originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Merck KGaA’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Merck KGaA's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Merck KGaA’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Merck KGaA Stock
How much was the turnover of the company Merck KGaA compared to the previous year?
The revenue of Merck KGaA has increased by 2.53% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Merck KGaA?
The revenue of Merck KGaA is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Merck KGaA measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Merck KGaA so important for investors?
The revenue of Merck KGaA is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Merck KGaA pay?
Over the past 12 months, Merck KGaA paid a dividend of 2.2 EUR . This corresponds to a dividend yield of about 1.25 %. For the coming 12 months, Merck KGaA is expected to pay a dividend of 2.42 EUR.
What is the dividend yield of Merck KGaA?
The current dividend yield of Merck KGaA is 1.25 %.
When does Merck KGaA pay dividends?
Merck KGaA pays a quarterly dividend. This is distributed in the months of May, May, June, May.
How secure is the dividend of Merck KGaA?
Merck KGaA paid dividends every year for the past 26 years.
What is the dividend of Merck KGaA?
For the upcoming 12 months, dividends amounting to 2.42 EUR are expected. This corresponds to a dividend yield of 1.37 %.
In which sector is Merck KGaA located?
Merck KGaA is assigned to the 'Health' sector.
Wann musste ich die Aktien von Merck KGaA kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Merck KGaA from 5/2/2024 amounting to 2.2 EUR, you needed to have the stock in your portfolio before the ex-date on 4/29/2024.
When did Merck KGaA pay the last dividend?
The last dividend was paid out on 5/2/2024.
What was the dividend of Merck KGaA in the year 2023?
In the year 2023, Merck KGaA distributed 1.85 EUR as dividends.
In which currency does Merck KGaA pay out the dividend?
The dividends of Merck KGaA are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Merck KGaA stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank
Andere Kennzahlen von Merck KGaA
Our stock analysis for Merck KGaA Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Merck KGaA Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
